#AbbVie's #Qulipta has become the first #oralCGRPinhibitor to show efficacy in a phase 3 study involving #women with #menstrualmigraine, which is severe and tends to resist current treatments.
@pharmaphorum.bsky.social
@pharmaphorum.bsky.social#AbbVie's #Qulipta has become the first #oralCGRPinhibitor to show efficacy in a phase 3 study involving #women with #menstrualmigraine, which is severe and tends to resist current treatments.
@newsen.bsky.socialAbbVie Enhances Shareholder Value with Quarterly Dividend Announcement #United_States #Dividend #Stockholders #AbbVie #North_Chicago
@aboveayer.bsky.socialPlanefence ICAO: A70E5B
Flt: N554AV ABBVIE
First seen: 2026-09-09 14:50:03 EDT
Min Alt: 11325 ft MSL
Min Dist: 1.88 mi
planefence adsb - adsbexchange - link
@planesovermemphis.bsky.socialPlaneAlert ICAO: A70E5B
Owner: ABBVIE
Flt: N554AV GA6C
Time: 2026-09-09 11:48:39 CDT
Min Alt: 41000 ft
adsb planefence planealert by kx1t sdr-e adsbexchange flightaware faa
@overneworleans.possumsin.spacePlaneAlert ICAO: A70E5B Tail: N554AV Flt: N554AV
Owner: AbbVie
Aircraft: Gulfstream G600
2026-09-08 14:15:58 CDT
GA6C Civ Bizjet Biotech Pharmaceuticals AsSeenonTV
- wiki - adsbexchange
@planesovermemphis.bsky.socialPlaneAlert ICAO: A70E5B
Owner: ABBVIE
Flt: N554AV GA6C
Time: 2026-09-08 14:02:13 CDT
Min Alt: 45000 ft
adsb planefence planealert by kx1t sdr-e adsbexchange flightaware faa
@pennadsb.comPlaneAlert ICAO: A70E5B
Owner: ABBVIE
Flt: N554AV GA6C
Time: 2026-09-08 13:36:19 EDT
Min Alt: 43000 ft
adsb planefence planealert by kx1t - sdr-e adsbexchange flightaware faa
@aboveayer.bsky.socialPlanefence ICAO: A70E5B
Flt: N554AV ABBVIE
First seen: 2026-09-08 11:43:49 EDT
Min Alt: 11300 ft MSL
Min Dist: 1.88 mi
planefence adsb - adsbexchange - link
@jlsweekly.bsky.socialJLSW Daily Brief #091 (Sep 8): Shionogi's cefiderocol approved in Australia (TGA). Belite Bio files tinlarebant for Stargardt disease in Japan. AbbVie closes Apogee.
#Shionogi #AbbVie #LifeSciencesJapan
https://jlsweekly.substack.com/p/abbvieapogee109
@newsen.bsky.social@newsen.bsky.socialAbbVie's Phase 3 CERVINO Trial Results Show Promising Efficacy of Etentamig in Multiple Myeloma Patients #United_States #Multiple_Myeloma #AbbVie #North_Chicago #Etentamig
@newsen.bsky.socialAbbVie Enhances Immunology Pipeline with Successful Apogee Therapeutics Acquisition #United_States #AbbVie #North_Chicago #Immunology #Apogee_Therapeutics